alentis.ch | About

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
# START YOAST BLOCK # --------------------------- User-agent: * Disallow: Sitemap: https://alentis.ch/sitemap_index.xml # --------------------------- # END YOAST

Meta Tags

Title	About - Alentis
Description	THE CLAUDIN-1 About Team Board of Directors Investors Science CLDN1 Pipeline News Videos Careers Toggle website search Menu Close THE CLAUDIN-1 COMPANY First-in-class m
Keywords	N/A

Server Information

WebSite	alentis.ch
Host IP	94.231.106.215
Location	Denmark

Related Websites

                        Site
                        Rank
                    

More to Explore

alentis.ch Valuation

US$2,723,369

Last updated: 2023-05-09 01:34:06

alentis.ch has Semrush global rank of 3,886,475. alentis.ch has an estimated worth of US$ 2,723,369, based on its estimated Ads revenue. alentis.ch receives approximately 314,235 unique visitors each day. Its web server is located in Denmark, with IP address 94.231.106.215. According to SiteAdvisor, alentis.ch is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$2,723,369
Daily Ads Revenue	US$2,514
Monthly Ads Revenue	US$75,417
Yearly Ads Revenue	US$904,997
Daily Unique Visitors	20,949
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
alentis.ch.	A	3598	IP: 94.231.106.215
alentis.ch.	NS	3600	NS Record: ns1.curanet.dk.
alentis.ch.	NS	3600	NS Record: ns2.curanet.dk.
alentis.ch.	MX	3600	MX Record: 0 alentis-ch.mail.protection.outlook.com.
alentis.ch.	TXT	3600	TXT Record: MS=ms42500380
alentis.ch.	TXT	3600	TXT Record: v=spf1 include:spf.protection.outlook.com -all

HtmlToTextCheckTime:2023-05-09 01:34:06

About Team Board of Directors Investors Science CLDN1 Pipeline News Videos Careers Toggle website search Menu Close THE CLAUDIN-1 COMPANY First-in-class monoclonal antibodies against Claudin-1 (CLDN1), a novel target that plays a key role in reprogramming the tumor and tissue microenvironment Alentis Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough treatments for cancer and fibrotic diseases. Claudin-1 (CLDN1) is a member of the tight junction proteins family. During disease pathogenesis, CLDN1 expression is up-regulated and exposed outside of the tight junction. Exposed, non–tight junctional, CLDN1 drives carcinogenic and fibrogenic signaling in different organs. Alentis’ lead candidates are monoclonal antibodies that are highly selective for exposed and non-junctional CLDN1. Remodeling and stiffening of the extracellular matrix (ECM) is a key driver of end-stage organ failure, with downstream fibrotic disorders accounting for up to 45% of deaths in

HTTP Headers

HTTP/1.1 301 Moved Permanently
Connection: Keep-Alive
Content-Type: text/html; charset=UTF-8
X-UA-Compatible: IE=edge
X-Redirect-By: WordPress
Location: https://alentis.ch/
Date: Sun, 31 Oct 2021 01:09:50 GMT
Server: LiteSpeed
X-NF-Server: Yes

HTTP/2 200 
content-type: text/html; charset=UTF-8
x-ua-compatible: IE=edge
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
date: Sun, 31 Oct 2021 01:09:51 GMT
server: LiteSpeed
x-nf-server: Yes
alt-svc: quic=":443"; ma=2592000; v="43,46", h3-Q043=":443"; ma=2592000, h3-Q046=":443"; ma=2592000, h3-Q050=":443"; ma=2592000, h3-25=":443"; ma=2592000, h3-27=":443"; ma=2592000

alentis.ch valuation and analysis